Skip to content
Research/Sexual Health/Tadalafil

Tadalafil

Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor primarily used to treat erectile dysfunction and benign prostatic hyperplasia. It works by increasing blood flow to certain areas of the body, which can improve sexual function and potentially have cardiovascular benefits. Its role in longevity and health optimization is linked to improved vascular health and circulation.

Intelligence Profile

Research Papers

Recent studies have examined various therapeutic applications of tadalafil, focusing on its effects on conditions beyond erectile dysfunction (ED).

  1. Risk of Glaucoma: A multinational cohort study published in The British Journal of Ophthalmology explored the potential risk of glaucoma among patients using tadalafil for lower urinary tract symptoms (LUTS). The study provides insight into the long-term ocular safety of tadalafil.

  2. Peyronie’s Disease: A review in Sexual Medicine discussed tadalafil's role as an antifibrotic treatment during the early stages of active Peyronie's disease. This suggests a possible new use for tadalafil in managing fibrotic conditions.

  3. Post-Prostate Cancer ED: A systematic review and network meta-analysis published in The World Journal of Men's Health evaluated medical interventions for ED after prostate cancer treatment. Tadalafil is included among interventions, highlighting its potential effectiveness in this specific patient group.

  4. Biomarker Profiles: A randomized controlled trial in Naunyn-Schmiedeberg's Archives of Pharmacology assessed tadalafil's effects on various biomarker profiles in men with both benign prostatic hyperplasia (BPH) and ED. The study emphasized changes in endothelial, angiogenic, and metabolic markers, adding depth to the understanding of tadalafil’s benefits.

  5. Chronic Thromboembolic Pulmonary Hypertension: In a systematic review from Pulmonary Circulation, tadalafil was evaluated alongside other drugs targeting the NO-sGC-cGMP pathway. This study underscores tadalafil's broader impact on circulatory conditions.

Clinical trials also shed light on tadalafil's diverse applications:

  • Prostate Cancer: Phase 3 trial (NCT00931528) on tadalafil as a preventive measure for ED in prostate cancer patients receiving radiation therapy provides evidence of its protective benefits.
  • Erectile Dysfunction Treatments: A Phase 4 trial (NCT07602608) investigated tadalafil with platelet-rich plasma, suggesting combination therapies might enhance outcomes for ED.
  • Lower Urinary Tract Symptoms: A completed Phase 4 trial (NCT02431754) on tadalafil’s use for LUTS associated with benign prostatic hyperplasia further supports its role in urinary tract symptom management.

These studies and trials collectively indicate tadalafil's expanding therapeutic roles and safety profile, although further research is necessary to solidify these findings.

This content is for informational purposes only and is not a substitute for professional medical advice.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.